Physician profile
Syed Raza
NPI 1992903157
$1,662.04
in general payments reported to CMS, 2019-2025
18 companies · $629 in 2025
The $629 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $52.45 · 2021: $261 · 2022: $69.87 · 2023: $84.26 · 2024: $370 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039 · Education: $45.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.91 |
| Education | $45.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $269.40 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $175.30 | 2021-2024 | Farxiga |
| Nuwellis, INC. | $152.62 | 2021 | |
| Ardelyx, INC. | $139.47 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $123.18 | 2024-2025 | Lupkynis |
| Baxter Healthcare | $102.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $100.64 | 2019-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $98.74 | 2022-2023 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $90.48 | 2025 | |
| Nxstage Medical, INC. | $83.82 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $68.81 | 2024 | Velphoro |
| Travere Therapeutics, INC. | $62.85 | 2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $54.33 | 2024 | Terlivaz |
| Calliditas Therapeutics US INC. | $38.47 | 2025 | Tarpeyo |
| Kite Pharma, INC. | $37.62 | 2025 | Yescarta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.85 | 2025 | Tavneos |
| Lilly USA, LLC | $19.82 | 2025 | Jardiance |
| Vifor Pharma, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.